{
    "id": 29629,
    "fullName": "NCAM1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NCAM1 positive indicates the presence of NCAM1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4684,
        "geneSymbol": "NCAM1",
        "terms": [
            "NCAM1",
            "CD56",
            "MSK39",
            "NCAM"
        ]
    },
    "variant": "positive",
    "createDate": "03/28/2019",
    "updateDate": "03/28/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16613,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lorvotuzumab Mertansine (IMGN901) demonstrated safety and preliminary efficacy, resulted in a clinical benefit rate of 25.5% (24/94) and an objective response rate of 4.3% (4/94, 2 complete response, 2 partial response) in patients with NCAM1 (CD56)-positive solid tumors, with a median progression-free survival and time to progression of 2.1 months, and a median overall survival of 9.2 months (PMID: 26961907; NCT00346385).",
            "molecularProfile": {
                "id": 31711,
                "profileName": "NCAM1 positive"
            },
            "therapy": {
                "id": 8107,
                "therapyName": "Lorvotuzumab Mertansine",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14639,
                    "pubMedId": 26961907,
                    "title": "Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26961907"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16615,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lorvotuzumab Mertansine (IMGN901) demonstrated safety and preliminary efficacy, resulted in a clinical benefit rate of 33.3% (4/12, 4 stable disease) in patients with NCAM1 (CD56)-positive ovarian cancer (PMID: 26961907; NCT00346385).",
            "molecularProfile": {
                "id": 31711,
                "profileName": "NCAM1 positive"
            },
            "therapy": {
                "id": 8107,
                "therapyName": "Lorvotuzumab Mertansine",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14639,
                    "pubMedId": 26961907,
                    "title": "Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26961907"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16616,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lorvotuzumab Mertansine (IMGN901) demonstrated safety and preliminary efficacy, resulted in a clinical benefit rate of 21.2% (7/33, 1 partial response, 6 stable disease) in patients with NCAM1 (CD56)-positive small cell lung cancer (PMID: 26961907; NCT00346385).",
            "molecularProfile": {
                "id": 31711,
                "profileName": "NCAM1 positive"
            },
            "therapy": {
                "id": 8107,
                "therapyName": "Lorvotuzumab Mertansine",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14639,
                    "pubMedId": 26961907,
                    "title": "Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26961907"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16614,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lorvotuzumab Mertansine (IMGN901) demonstrated safety and preliminary efficacy, resulted in an objective response rate of 13% (3/23, 2 complete response, 1 partial response) in patients with NCAM1 (CD56)-positive Merkel cell carcinoma, with 2 additional patients achieved stable disease as best response (PMID: 26961907; NCT00346385).",
            "molecularProfile": {
                "id": 31711,
                "profileName": "NCAM1 positive"
            },
            "therapy": {
                "id": 8107,
                "therapyName": "Lorvotuzumab Mertansine",
                "synonyms": null
            },
            "indication": {
                "id": 3965,
                "name": "Merkel cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14639,
                    "pubMedId": 26961907,
                    "title": "Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26961907"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16612,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Lorvotuzumab Mertansine (IMGN901) demonstrated safety and preliminary efficacy, resulted in partial response in 5.7% (2/35), minor response in 11.4% (4/35), and stable disease in 42.9% (15/35) of patients with NCAM1 (CD56)-positive relapsed and relapsed-refractory multiple myeloma, with a median progression-free survival of 26.1 weeks (PMID: 30340993; NCT00346255).",
            "molecularProfile": {
                "id": 31711,
                "profileName": "NCAM1 positive"
            },
            "therapy": {
                "id": 8107,
                "therapyName": "Lorvotuzumab Mertansine",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14638,
                    "pubMedId": 30340993,
                    "title": "A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30340993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31711,
            "profileName": "NCAM1 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}